What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Elranatamab has not been directly compared in a clinical trial with the main comparator, pomalidomide plus dexamethasone, which limits the strength of the evidence. Indirect comparisons suggest potential benefits in terms of progression-free survival (PFS) and overall survival (OS), but the lack of direct evidence and ongoing trials introduce significant uncertainty regarding its clinical effectiveness.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for elranatamab are uncertain and likely above NICE’s acceptable thresholds. The committee noted that while elranatamab could be cost-effective with further evidence, current estimates do not support routine use without managed access.
Is there quality-of-life evidence payers weigh? — Quality of life
The treatment is reported to provide psychological benefits and convenience due to its subcutaneous administration, which may improve patient quality of life. However, specific validated HRQoL data is not detailed in the document, leading to a moderate rating.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Elranatamab has a good safety profile, with manageable adverse events. The document indicates that it does not require steroids, which is a significant advantage over other treatments. However, the potential for infections necessitates monitoring and possible IVIg use.
Was the drug compared against what payers expect? — Comparator Selection
The main comparator, pomalidomide plus dexamethasone, was not directly tested against elranatamab, which raises concerns about the validity of the comparisons made. The committee acknowledged that the indirect comparisons were not ideal.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population is described as triple-class refractory, which is representative of a significant subgroup of patients with relapsed and refractory multiple myeloma. However, there are concerns about generalizability to all patients eligible for treatment.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Elranatamab can be integrated into existing treatment pathways with minor adjustments, such as monitoring for infections. Its subcutaneous administration also facilitates easier integration into clinical practice compared to intravenous treatments.
Are the wider system costs understood? — Resource Use and Cost Implications
The resource implications of elranatamab are significant, particularly regarding the potential need for IVIg and monitoring. The committee noted that the overall cost burden could be high, raising concerns about affordability.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base is primarily from a phase 2 trial with ongoing studies, leading to concerns about the robustness and maturity of the data. The lack of a randomized controlled trial further limits the strength of the evidence.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There are significant uncertainties regarding long-term outcomes and the impact of IVIg use. The committee noted that the evidence base is immature, which could lead to restricted use until further data is available.
